Identification of the first large deletion in the CLDN16 gene in a patient with FHHNC and late-onset of chronic kidney disease: case report

BMC Nephrology

Francisco de Assis Rocha Neves⁴  Ana Carolina Acevedo⁶  Juliana Forte Mazzeu³  Viviane Brandão Bandeira de Mello Santana¹  Bruno Sakamoto Leal²  Pollyanna Almeida Costa dos Santos⁶  Paulo Marcio Yamaguti⁵ 

[1] Nephrology Division, Hospital de Base de Brasilia, Soclimed Nephrology and Dialysis Unit, Brasilia, Brazil;Faculty of Medicine, University of Brasilia, Brasilia, Brazil;Laboratory of Genetics, Faculty of Medicine, Faculty of Health Sciences, University of Brasilia, Brasilia, Brazil;Laboratório de Farmacologia Molecular, Faculdade de Ciências da Saúde, Universidade de Brasília, Campus Universitário Darcy Ribeiro, Brasília, Brazil;University Hospital of Brasilia, University of Brasilia, Brasilia, Brazil;Laboratory of Oral Histopathology, Faculty of Health Sciences, University of Brasilia, Brasilia, Brazil

关键词: Nephrocalcinosis;    Hypomagnesemia;    Hypercalciuria;    Claudin-16;    CLDN16;   

Others  :  1220028
DOI  :  10.1186/s12882-015-0079-4

 received in 2015-02-05, accepted in 2015-05-27,  发布年份 2015

【 摘 要 】

Background

Familial hypomagnesemia with hypercalciuria and nephrocalcinosis is a rare autosomal recessive renal disease characterized by tubular disorders at the thick ascending limb of Henle’s loop. It is caused by mutations in the tight junction structural proteins claudin-16 or claudin-19, which are encoded by the CLDN16 and CLDN19 genes, respectively. Patients exhibit excessive wasting of calcium and magnesium, nephrocalcinosis, chronic kidney disease, and early progression to end-stage renal failure during infancy.

Case presentation

We here report the phenotype and molecular analysis of a female Brazilian patient with a novel large homozygous deletion in the CLDN16 gene. The proband, born from consanguineous parents, presented the first symptoms at age 20. Clinical examination revealed hypocalcemia, hypomagnesemia, nephrocalcinosis, mild myopia, high serum levels of uric acid and intact parathyroid hormone, and moderate chronic kidney disease (stage 3). She and her mother were subjected to CLDN16 and CLDN19 mutational analysis. In addition, the multiplex ligation-dependent probe amplification method was used to confirm a CLDN16 multi-exon deletion. Direct sequencing revealed a normal CLDN19 sequence and suggested a large deletion in the CLDN16 gene. Multiplex ligation-dependent probe amplification showed a homozygous CLDN16 multi-exon deletion (E2_E5del). The patient initiated conventional treatment for familial hypomagnesemia with hypercalciuria and nephrocalcinosis and progressed to end-stage kidney disease after five years.

Conclusions

This study provides the first report of a large homozygous deletion in the CLDN16 gene causing familial hypomagnesemia with hypercalciuria and nephrocalcinosis with late onset of the first symptoms. This description expands the phenotypic and genotypic characterization of the disease. The late-onset chronic kidney disease in the presence of a homozygous deletion in the CLDN16 gene reinforces the great variability of genotype-phenotype manifestation in patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis.

【 授权许可】

   
2015 Yamaguti et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Weber S, Hoffmann K, Jeck N, Saar K, Boeswald M, Kuwertz-Broeking E, Meij II, Knoers NV, Cochat P, Sulakova T et al.. Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis maps to chromosome 3q27 and is associated with mutations in the PCLN-1 gene. Eur J Hum Genet. 2000; 8(6):414-22.
• [2]Konrad M, Schaller A, Seelow D, Pandey AV, Waldegger S, Lesslauer A, Vitzthum H, Suzuki Y, Luk JM, Becker C et al.. Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet. 2006; 79(5):949-57.
• [3]Simon DB, Lu Y, Choate KA, Velazquez H, Al-Sabban E, Praga M, Casari G, Bettinelli A, Colussi G, Rodriguez-Soriano J et al.. Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science. 1999; 285(5424):103-6.
• [4]Miyamoto T, Morita K, Takemoto D, Takeuchi K, Kitano Y, Miyakawa T, Nakayama K, Okamura Y, Sasaki H, Miyachi Y et al.. Tight junctions in Schwann cells of peripheral myelinated axons: a lesson from claudin-19-deficient mice. J Cell Biol. 2005; 169(3):527-38.
• [5]Hou J, Renigunta A, Konrad M, Gomes AS, Schneeberger EE, Paul DL, Waldegger S, Goodenough DA. Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. J Clin Invest. 2008; 118(2):619-28.
• [6]Hou J, Renigunta A, Gomes AS, Hou M, Paul DL, Waldegger S, Goodenough DA. Claudin-16 and claudin-19 interaction is required for their assembly into tight junctions and for renal reabsorption of magnesium. Proc Natl Acad Sci U S A. 2009; 106(36):15350-5.
• [7]Hou J, Paul DL, Goodenough DA. Paracellin-1 and the modulation of ion selectivity of tight junctions. J Cell Sci. 2005; 118(Pt 21):5109-18.
• [8]Gunzel D, Yu AS. Function and regulation of claudins in the thick ascending limb of Henle. Pflugers Arch. 2009; 458(1):77-88.
• [9]Will C, Breiderhoff T, Thumfart J, Stuiver M, Kopplin K, Sommer K, Gunzel D, Querfeld U, Meij IC, Shan Q et al.. Targeted deletion of murine Cldn16 identifies extra- and intrarenal compensatory mechanisms of Ca2+ and Mg2+ wasting. Am J Physiol Renal Physiol. 2010; 298(5):F1152-61.
• [10]Shan Q, Himmerkus N, Hou J, Goodenough DA, Bleich M. Insights into driving forces and paracellular permeability from claudin-16 knockdown mouse. Ann N Y Acad Sci. 2009; 1165:148-51.
• [11]Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Boswald M, Bonzel KE, Seeman T, Sulakova T, Kuwertz-Broking E et al.. Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol. 2001; 12(9):1872-81.
• [12]Godron A, Harambat J, Boccio V, Mensire A, May A, Rigothier C, Couzi L, Barrou B, Godin M, Chauveau D et al.. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: phenotype-genotype correlation and outcome in 32 patients with CLDN16 or CLDN19 mutations. Clin J Am Soc Nephrol. 2012; 7(5):801-9.
• [13]Faguer S, Chauveau D, Cintas P, Tack I, Cointault O, Rostaing L, Vargas-Poussou R, Ribes D. Renal, ocular, and neuromuscular involvements in patients with CLDN19 mutations. Clin J Am Soc Nephrol. 2011; 6(2):355-60.
• [14]Claverie-Martin F, Garcia-Nieto V, Loris C, Ariceta G, Nadal I, Espinosa L, Fernandez-Maseda A, Anton-Gamero M, Avila A, Madrid A et al.. Claudin-19 mutations and clinical phenotype in Spanish patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. PLoS One. 2013; 8(1):e53151.
• [15]Konrad M, Hou J, Weber S, Dotsch J, Kari JA, Seeman T, Kuwertz-Broking E, Peco-Antic A, Tasic V, Dittrich K et al.. CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol. 2008; 19(1):171-81.
• [16]Wolf MT, Dotsch J, Konrad M, Boswald M, Rascher W. Follow-up of five patients with FHHNC due to mutations in the Paracellin-1 gene. Pediatr Nephrol. 2002; 17(8):602-8.
• [17]Seeley HH, Loomba-Albrecht LA, Nagel M, Butani L, Bremer AA. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis in three siblings having the same genetic lesion but different clinical presentations. World J Pediatr. 2012; 8(2):177-80.
• [18]Stern RF, Roberts RG, Mann K, Yau SC, Berg J, Ogilvie CM. Multiplex ligation-dependent probe amplification using a completely synthetic probe set. Biotechniques. 2004; 37(3):399-405.
• [19]Tsukita S, Furuse M. The structure and function of claudins, cell adhesion molecules at tight junctions. Ann N Y Acad Sci. 2000; 915:129-35.
• [20]Muller D, Kausalya PJ, Bockenhauer D, Thumfart J, Meij IC, Dillon MJ, van’t Hoff W, Hunziker W. Unusual clinical presentation and possible rescue of a novel claudin-16 mutation. J Clin Endocrinol Metab. 2006; 91(8):3076-9.
• [21]Hou J, Shan Q, Wang T, Gomes AS, Yan Q, Paul DL, Bleich M, Goodenough DA. Transgenic RNAi depletion of claudin-16 and the renal handling of magnesium. J Biol Chem. 2007; 282(23):17114-22.
• [22]Benigno V, Canonica CS, Bettinelli A, von Vigier RO, Truttmann AC, Bianchetti MG. Hypomagnesaemia-hypercalciuria-nephrocalcinosis: a report of nine cases and a review. Nephrol Dial Transplant. 2000; 15(5):605-10.
• [23]Kari JA, Farouq M, Alshaya HO. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003; 18(6):506-10.
• [24]Hou J, Rajagopal M, Yu AS. Claudins and the kidney. Annu Rev Physiol. 2013; 75:479-501.
• [25]Hou J. The yin and yang of claudin-14 function in human diseases. Ann N Y Acad Sci. 2012; 1258:185-90.
• [26]Hou J, Goodenough DA. Claudin-16 and claudin-19 function in the thick ascending limb. Curr Opin Nephrol Hypertens. 2010; 19(5):483-8.
• [27]Turkmen M, Kasap B, Soylu A, Bober E, Konrad M, Kavukcu S. Paracellin-1 gene mutation with multiple congenital abnormalities. Pediatr Nephrol. 2006; 21(11):1776-8.
• [28]Kutluturk F, Temel B, Uslu B, Aral F, Azezli A, Orhan Y, Konrad M, Ozbey N. An unusual patient with hypercalciuria, recurrent nephrolithiasis, hypomagnesemia and G227R mutation of Paracellin-1. An unusual patient with hypercalciuria and hypomagnesemia unresponsive to thiazide diuretics Horm Res. 2006; 66(4):175-81.
• [29]Al-Haggar M, Bakr A, Tajima T, Fujieda K, Hammad A, Soliman O, Darwish A, Al-Said A, Yahia S, Abdel-Hady D. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: unusual clinical associations and novel claudin16 mutation in an Egyptian family. Clin Exp Nephrol. 2009; 13(4):288-94.
• [30]Nadarajah L, Khosravi M, Dumitriu S, Klootwijk E, Kleta R, Yaqoob MM, Walsh SB. A novel claudin-16 mutation, severe bone disease, and nephrocalcinosis. Lancet. 2014; 383(9911):98.